RhumbLine Advisers
NPCE icon

RhumbLine Advisers’s Neuropace NPCE Stock Holding History

RhumbLine Advisers’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$503K Buy
31,664
+2,218
+8% +$35.7K ﹤0.01% 2765
2026
Q1 		$387K Buy
29,446
+139
+0.5% +$2.08K ﹤0.01% 2768
2025
Q4 		$452K Sell
29,307
-2,726
-9% -$36.5K ﹤0.01% 2732
2025
Q3 		$330K Sell
32,033
-4,923
-13% -$46.4K ﹤0.01% 2930
2025
Q2 		$412K Buy
36,956
+19,729
+115% +$247K ﹤0.01% 2802
2025
Q1 		$212K Buy
17,227
+2,267
+15% +$28.4K ﹤0.01% 3078
2024
Q4 		$167K Buy
14,960
+634
+4% +$5.51K ﹤0.01% 3284
2024
Q3 		$99.8K Sell
14,326
-338
-2% -$2.47K ﹤0.01% 3495
2024
Q2 		$111K Buy
+14,664
New +$148K ﹤0.01% 3489

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

RhumbLine Advisers's NPCE Position: Q2 2026 in Review

RhumbLine Advisers increased its Neuropace (NPCE) stake by 7.5% in Q2 2026, buying an estimated $35.7K and bringing the position to 31,664 shares worth $503K. The position accounts for ﹤0.01% of the portfolio, ranked #2765.

RhumbLine Advisers first reported a position in NPCE in Q2 2024 and has held it in 9 quarters since. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • RhumbLine Advisers held 31,664 shares of Neuropace worth $503K as of Q2 2026.
  • RhumbLine Advisers bought 2,218 Neuropace shares in Q2 2026, an estimated $35.7K.
  • Neuropace made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2765 holding.
  • RhumbLine Advisers first reported a position in Neuropace in Q2 2024 and has held it in 9 quarters since.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.